Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 45Cyclophosphamide 32fludarabine phosphate 28fludarabine 19ibrutinib 17Peripheral Blood Stem Cell Transplantation 17Lenalidomide 17venetoclax 13Mycophenolic Acid 10Cyclosporine 10acalabrutinib 9Whole-Body Irradiation 9Filgrastim 9obinutuzumab 7Bendamustine Hydrochloride 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Melphalan 6Prednisone 5Etoposide 5Busulfan 5zanubrutinib 4pirtobrutinib 4aldesleukin 4Vincristine 4Tacrolimus 4Indium 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Lymphocytic, Chronic, B-Cell × oprelvekin × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡